|
Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation |
Main C, Bojke L, Griffin S, Norman G, Barbieri M, Mather L, Stark D, Palmer S, Riemsma R |
|
|
Record Status This is an economic evaluation that meets the criteria for inclusion on NHS EED. Bibliographic details Main C, Bojke L, Griffin S, Norman G, Barbieri M, Mather L, Stark D, Palmer S, Riemsma R. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation. Health Technology Assessment 2006; 10(9): 1-148 Indexing Status Subject indexing assigned by NLM MeSH Antibiotics, Antineoplastic /adverse effects /economics /therapeutic use; Antineoplastic Agents /adverse effects /economics /therapeutic use; Cost-Benefit Analysis; Doxorubicin /adverse effects /economics /therapeutic use; Female; Humans; Liposomes; Ovarian Neoplasms /drug therapy /economics /mortality; Paclitaxel /adverse effects /economics /therapeutic use; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Survival Analysis; Topotecan /adverse effects /economics /therapeutic use AccessionNumber 22006008229 Date bibliographic record published 07/04/2006 |
|
|
|